Correlation Engine 2.0
Clear Search sequence regions

  • Akt (3)
  • Akt1 (9)
  • Akt2 (6)
  • breast cancer (5)
  • breast metastasis (2)
  • ErbB 2 (2)
  • ErbB2 (2)
  • female (1)
  • gene (1)
  • humans (1)
  • insulin (4)
  • isoform (1)
  • metastasis (5)
  • neutrophils (4)
  • receptor erbb- 2 (2)
  • Sizes of these terms reflect their relevance to your search.

    Studies in three mouse models of breast cancer identified profound discrepancies between cell-autonomous and systemic Akt1- or Akt2-inducible deletion on breast cancer tumorigenesis and metastasis. Although systemic Akt1 deletion inhibits metastasis, cell-autonomous Akt1 deletion does not. Single-cell mRNA sequencing revealed that systemic Akt1 deletion maintains the pro-metastatic cluster within primary tumors but ablates pro-metastatic neutrophils. Systemic Akt1 deletion inhibits metastasis by impairing survival and mobilization of tumor-associated neutrophils. Importantly, either systemic or neutrophil-specific Akt1 deletion is sufficient to inhibit metastasis of Akt-proficient tumors. Thus, Akt1-specific inhibition could be therapeutic for breast cancer metastasis regardless of primary tumor origin. Systemic Akt2 deletion does not inhibit and exacerbates mammary tumorigenesis and metastasis, but cell-autonomous Akt2 deletion prevents breast cancer tumorigenesis by ErbB2. Elevated circulating insulin level induced by Akt2 systemic deletion hyperactivates tumor Akt, exacerbating ErbB2-mediated tumorigenesis, curbed by pharmacological reduction of the elevated insulin. Copyright © 2020 Elsevier Inc. All rights reserved.


    Xinyu Chen, Majd M Ariss, Gopalakrishnan Ramakrishnan, Veronique Nogueira, Catherine Blaha, William Putzbach, Abul B M M K Islam, Maxim V Frolov, Nissim Hay. Cell-Autonomous versus Systemic Akt Isoform Deletions Uncovered New Roles for Akt1 and Akt2 in Breast Cancer. Molecular cell. 2020 Oct 01;80(1):87-101.e5

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 32931746

    View Full Text